Intellia Therapeutics (NTLA) Cash & Equivalents (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash & Equivalents data on file, last reported at $134.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 6.16% year-over-year to $134.7 million in Q1 2026; TTM through Mar 2026 was $134.7 million, a 6.16% increase from a year earlier, with the FY2025 full-year figure at $155.5 million, down 17.82% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $134.7 million, down from $155.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NTLA reached as high as $294.2 million in Q1 2023 and fell as low as $12.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $147.9 million across 5 years, with a median of $147.8 million in 2022.
• On a YoY basis, Cash & Equivalents climbed as much as 1796.36% in 2023 and fell as far as 91.91% in 2023.
• Year by year, Cash & Equivalents stood at $12.0 million in 2022, then soared by 1796.36% to $226.7 million in 2023, then declined by 16.57% to $189.2 million in 2024, then declined by 17.82% to $155.5 million in 2025, then retreated by 13.36% to $134.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $134.7 million in Q1 2026, $155.5 million in Q4 2025, and $193.4 million in Q3 2025.